Vaxart (VXRT) Competitors $0.44 +0.01 (+3.39%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VXRT vs. ATAI, PVLA, AURA, CYRX, GLUE, PHAT, RNAC, TSVT, MNPR, and SEPNShould you be buying Vaxart stock or one of its competitors? The main competitors of Vaxart include Atai Life Sciences (ATAI), Palvella Therapeutics (PVLA), Aura Biosciences (AURA), Cryoport (CYRX), Monte Rosa Therapeutics (GLUE), Phathom Pharmaceuticals (PHAT), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Monopar Therapeutics (MNPR), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry. Vaxart vs. Atai Life Sciences Palvella Therapeutics Aura Biosciences Cryoport Monte Rosa Therapeutics Phathom Pharmaceuticals Cartesian Therapeutics 2seventy bio Monopar Therapeutics Septerna Vaxart (NASDAQ:VXRT) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, community ranking, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Do insiders and institutionals have more ownership in VXRT or ATAI? 18.0% of Vaxart shares are owned by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are owned by institutional investors. 2.6% of Vaxart shares are owned by company insiders. Comparatively, 31.2% of Atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is VXRT or ATAI more profitable? Atai Life Sciences has a net margin of 0.00% compared to Vaxart's net margin of -431.61%. Atai Life Sciences' return on equity of -65.75% beat Vaxart's return on equity.Company Net Margins Return on Equity Return on Assets Vaxart-431.61% -110.46% -62.78% Atai Life Sciences N/A -65.75%-52.71% Which has stronger valuation and earnings, VXRT or ATAI? Atai Life Sciences has lower revenue, but higher earnings than Vaxart. Atai Life Sciences is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxart$28.70M3.50-$82.46M-$0.34-1.29Atai Life Sciences$308K973.03-$40.22M-$0.93-1.61 Does the MarketBeat Community favor VXRT or ATAI? Atai Life Sciences received 23 more outperform votes than Vaxart when rated by MarketBeat users. Likewise, 66.53% of users gave Atai Life Sciences an outperform vote while only 65.61% of users gave Vaxart an outperform vote. CompanyUnderperformOutperformVaxartOutperform Votes31165.61% Underperform Votes16334.39% Atai Life SciencesOutperform Votes33466.53% Underperform Votes16833.47% Do analysts rate VXRT or ATAI? Vaxart presently has a consensus price target of $3.00, suggesting a potential upside of 582.44%. Atai Life Sciences has a consensus price target of $10.50, suggesting a potential upside of 600.00%. Given Atai Life Sciences' higher possible upside, analysts clearly believe Atai Life Sciences is more favorable than Vaxart.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxart 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, VXRT or ATAI? Vaxart has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Does the media favor VXRT or ATAI? In the previous week, Vaxart had 1 more articles in the media than Atai Life Sciences. MarketBeat recorded 2 mentions for Vaxart and 1 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 1.89 beat Vaxart's score of 0.65 indicating that Atai Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Vaxart Positive Atai Life Sciences Very Positive SummaryAtai Life Sciences beats Vaxart on 12 of the 17 factors compared between the two stocks. Get Vaxart News Delivered to You Automatically Sign up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VXRT vs. The Competition Export to ExcelMetricVaxartBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$100.32M$3.00B$5.56B$7.83BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-1.0730.4222.4818.48Price / Sales3.50498.92394.56103.59Price / CashN/A168.6838.1834.62Price / Book1.163.206.774.25Net Income-$82.46M-$72.35M$3.22B$248.23M7 Day Performance22.11%1.46%1.48%0.89%1 Month Performance18.01%8.79%3.99%3.53%1 Year Performance-37.25%-22.36%16.15%5.08% Vaxart Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VXRTVaxart1.4814 of 5 stars$0.44+3.4%$3.00+582.4%-38.5%$100.32M$28.70M-1.07120News CoverageATAIAtai Life Sciences2.6737 of 5 stars$1.42-3.4%$10.50+639.4%-24.2%$283.69M$308,000.00-1.7580Positive NewsPVLAPalvella Therapeutics3.4225 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AAnalyst ForecastHigh Trading VolumeAURAAura Biosciences2.3414 of 5 stars$5.57+3.9%$22.75+308.4%-21.2%$279.75MN/A-3.2250Upcoming EarningsShort Interest ↑Positive NewsGap DownCYRXCryoport2.3918 of 5 stars$5.52-0.5%$11.67+111.4%-65.5%$275.50M$228.39M-1.631,020Gap DownGLUEMonte Rosa Therapeutics1.9756 of 5 stars$4.46-2.0%$15.50+247.5%-7.7%$274.34M$75.62M-2.4490Upcoming EarningsShort Interest ↑Positive NewsPHATPhathom Pharmaceuticals4.0385 of 5 stars$3.90-3.2%$21.83+459.8%-52.5%$271.58M$55.25M-0.69110Positive NewsRNACCartesian Therapeutics1.9551 of 5 stars$10.34-1.5%$42.14+307.6%-45.6%$267.88M$38.91M-0.2064Upcoming EarningsGap DownTSVT2seventy bio1.7351 of 5 stars$4.99+0.2%$5.60+12.2%+9.4%$261.17M$37.86M-2.68440Short Interest ↑News CoverageMNPRMonopar Therapeutics3.0979 of 5 stars$42.71+7.9%$55.33+29.6%+1,167.1%$261.09MN/A-21.6810Upcoming EarningsNews CoveragePositive NewsGap DownSEPNSepterna2.2586 of 5 stars$5.87-0.5%$33.00+462.2%N/A$260.88M$1.08M0.00N/ANews CoveragePositive News Related Companies and Tools Related Companies Atai Life Sciences Competitors Palvella Therapeutics Competitors Aura Biosciences Competitors Cryoport Competitors Monte Rosa Therapeutics Competitors Phathom Pharmaceuticals Competitors Cartesian Therapeutics Competitors 2seventy bio Competitors Monopar Therapeutics Competitors Septerna Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VXRT) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxart, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxart With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VXRT Stock Free VXRT Stock Alerts